Head-To-Head Analysis: Definium Therapeutics (NASDAQ:DFTX) and HAVN Life Sciences (OTCMKTS:HAVLF)

Definium Therapeutics (NASDAQ:DFTX) and HAVN Life Sciences (OTCMKTS:HAVLF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Definium Therapeutics and HAVN Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1	0	12	2	3.00
HAVN Life Sciences	0	0	0	0	0.00

Definium Therapeutics presently has a consensus price target of $37.92, indicating a potential upside of 81.71%. Given Definium Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Definium Therapeutics is more favorable than HAVN Life Sciences.

Institutional & Insider Ownership

27.9% of Definium Therapeutics shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Definium Therapeutics and HAVN Life Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79 million	($2.49)	-8.38
HAVN Life Sciences	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Definium Therapeutics and HAVN Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
HAVN Life Sciences	N/A	N/A	N/A

Summary

Definium Therapeutics beats HAVN Life Sciences on 6 of the 8 factors compared between the two stocks.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About HAVN Life Sciences

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.